BCYC Key Statistics, Chart & Performance
The current stock price of BCYC is 6.49 USD. In the past month the price decreased by -2.84%. In the past year, price decreased by -46.72%.
BCYC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BCYC. When comparing the yearly performance of all stocks, BCYC is a bad performer in the overall market: 87.08% of all stocks are doing better.
BCYC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BCYC. No worries on liquidiy or solvency for BCYC as it has an excellent financial health rating, but there are worries on the profitability.
BCYC Financial Highlights
Over the last trailing twelve months BCYC reported a non-GAAP Earnings per Share(EPS) of -3.69. The EPS decreased by -12.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.81% | ||
| ROE | -40.53% | ||
| Debt/Equity | 0 |
BCYC Forecast & Estimates
20 analysts have analysed BCYC and the average price target is 20.91 USD. This implies a price increase of 222.19% is expected in the next year compared to the current price of 6.49.
For the next year, analysts expect an EPS growth of -33.25% and a revenue growth -13.15% for BCYC
BCYC Ownership
BCYC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.88 | 398.79B | ||
| AMGN | AMGEN INC | 15.76 | 185.60B | ||
| GILD | GILEAD SCIENCES INC | 17.45 | 177.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.19 | 119.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.01 | 79.35B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 664.92 | 44.80B | ||
| INSM | INSMED INC | N/A | 32.84B | ||
| NTRA | NATERA INC | N/A | 31.89B | ||
| BIIB | BIOGEN INC | 10.7 | 26.27B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18 | 20.45B | ||
| INCY | INCYTE CORP | 15.99 | 20.16B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.45B |
Related stock screener links
About BCYC
Company Profile
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 305 full-time employees. The company went IPO on 2019-05-23. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The firm is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Company Info
BICYCLE THERAPEUTICS PLC-ADR
Blocks A & B, Portway Building, Granta Park, Great Abington
Cambridge CAMBRIDGESHIRE CB22 3AT GB
CEO: Kevin Lee
Employees: 305
Phone: 11441223261503
BICYCLE THERAPEUTICS PLC-ADR / BCYC FAQ
What does BCYC do?
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 305 full-time employees. The company went IPO on 2019-05-23. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The firm is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Can you provide the latest stock price for BICYCLE THERAPEUTICS PLC-ADR?
The current stock price of BCYC is 6.49 USD. The price increased by 1.09% in the last trading session.
Does BCYC stock pay dividends?
BCYC does not pay a dividend.
What is the ChartMill technical and fundamental rating of BCYC stock?
BCYC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the number of employees for BICYCLE THERAPEUTICS PLC-ADR?
BICYCLE THERAPEUTICS PLC-ADR (BCYC) currently has 305 employees.
What is BICYCLE THERAPEUTICS PLC-ADR worth?
BICYCLE THERAPEUTICS PLC-ADR (BCYC) has a market capitalization of 450.20M USD. This makes BCYC a Small Cap stock.
When does BICYCLE THERAPEUTICS PLC-ADR (BCYC) report earnings?
BICYCLE THERAPEUTICS PLC-ADR (BCYC) will report earnings on 2026-02-23, after the market close.